Breaking News
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Arrowhead Pharmaceuticals announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).
“MMP7 is thought to play multiple roles in IPF pathogenesis, including promoting inflammation and aberrant epithelial repair and fibrosis,” said James Hamilton, M.D., MBA, chief of discovery and translational medicine at Arrowhead. “ARO-MMP7 offers a novel approach to potentially address the significant unmet medical need that exists for patients with IPF, who experience progressive decline of lung function, despite currently available therapies.”
AROMMP7-1001 (NCT05537025) is a Phase 1/2a single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7 in up to 56 healthy volunteers and up to 21 patients with IPF.
- Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
- NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
- Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
- Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
- Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more
Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients […]
Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced it has […]
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
Nanoscope Therapeutics, today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE […]
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
CANbridge Pharmaceuticals, a global biopharmaceutical company, with a foundation in China, committed to the research, […]
NRx Pharmaceuticals to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression
NRx Pharmaceuticals, a clinical-stage CNS biopharmaceutical company, today reported that the independent Data Safety Monitoring […]
FDA Issues Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval
The United States Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to […]
Novartis Trial Shows Benefit in Patients with Breast Cancer
Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III […]
Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients […]
NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business
NEC Corporation and NOI announced that NOI will be realigned as a subsidiary of NEC […]
Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
Sensorion, a pioneering clinical-stage biotechnology company that specializes in gene therapies in the ear, announces […]
Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China
Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy (TRT) to benefit […]
Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced it has […]
ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment
ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment […]